摘要
【目的】探讨华蟾素肝动脉推注联合热灌注化疗治疗原发性肝癌的临床疗效。【方法】76例原发性肝癌患者随机分为两组.各38例。对照组采取经动脉热灌注化疗后经动脉化疗栓塞(TACE),观察组采取华蟾素肝动脉推注联合热灌注化疗后TACE.均治疗3次,每次间隔1个月。比较两组疗效、不良反应发生率及无进展生存期(PFS)、总生存期(OS)。【结果】观察组疾病控制率为63.16%(24/38),高于对照组的41.67%(20/38),但两组之间比较差异无显著性(P>0.05)。观察组疼痛发生率为36.84%(14/38),显著低于对照组的63.16%(24/38),且两组相比较差异有显著性(PV0.05)。观察组PFS为(12.01土2.89)个月,OS为(19.32士5.48)个月,均显著高于对照组的(10.03±3.00)个月和(15.43土4.82)个月.且两组相比较差异均有显著性(均P<0.05).【结论】华蟾素肝动脉推注联合热灌注化疗治疗原发性肝癌的抗肿瘤效果更佳,患者生存期得以延长且疼痛减轻,值得临床推广。
[Objective]To investigate the clinical effect of cinobufotalin injection through hepatic artery combined with hyperthermic perfusion chemotherapy in the treatment of primary hepatocellular carcinoma.[Methods] Seventy-six patients with primary liver cancer were randomly divided into two groups, 38 cases each. The control group received transcatheter arterial chemoembolization (TACE) after transcatheter arterial in fusion chemotherapy, while the observation group received hepatic artery injection of cinobufotalin combi ned with transcatheter arterial infusion chemotherapy (TACE) three times, one month apart. The efficacy, incidence of adverse reactions, PFS and OS of the two groups were compared.!ResultsJThe disease control rate of the observation group was 63.16%(24/38), higher than that of the control group 41.67%(20/38), but there was no significant difference between the two groups ( P >0.05). The incidence of pain in the observation group was 36.84%(14/38), significantly lower than that in the control group 63.16%(24/38). and there was a significant difference between the two groups ( P <0.05). The PFS and OS of the observation group were (12.01 ±2.89) months and (19.32± 5.48) months, which were significantly higher than those of the control group (10.03 ±3.00) months and (15.43 ±4.82) months, and there were significant differences between the two groups (all P <0.05).[ Conclusion ] The anti-tumor effect of cinobufotalin intrahepatic artery injection combined with hyperthermic perfusion chemotherapy for primary hepatocellular carcinoma is better, the survival time of patients is prolonged and the pain is alleviated, which is worthy of clinical promotion.
作者
蔡向阳
张东
CAI Xiang-yan;ZHANG Dong(People in Nanjiang County , Sichuan Province 636000)
出处
《医学临床研究》
CAS
2019年第7期1282-1284,共3页
Journal of Clinical Research
